Side-by-side financials for AUTL and GILD. Every figure below comes from audited SEC filings and refreshed market data.
| Metric | AUTL | GILD |
|---|---|---|
| Market cap | - | $150.83 B |
| US-listed rank | - | #99 |
| Revenue (latest FY) | $75.39M | $29.44B |
| Net income (latest FY) | -$287.53M | $8.51B |
| Net margin | -381.4% | 28.9% |
| P/E (trailing FY) | - | 17.7 |
| SEC filings | 305 | 981 |
In their latest fiscal years, Autolus Therapeutics plc reported $75.39M in revenue while GILEAD SCIENCES, INC. reported $29.44B.
Full pages: Autolus Therapeutics plc and GILEAD SCIENCES, INC., or browse the full rankings.